Overview

A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)

Status:
Completed

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

We hypothesize that PKDL develop after SSG as well as after Miltefosine mono-therapy for VL; anti-inflammatory cytokines such as IL-10, TGF-β, serum lipids play key role for its pathogenesis & PKDL patients are genetically predisposed; diagnostic tool based on immunofluorescence technique will be more sensitive than slit skin examination for diagnosis of PKDL.

Phase:

Phase 4

Details

Lead Sponsor:

International Centre for Diarrhoeal Disease Research, Bangladesh

Collaborator:

University of Nagasaki.

Treatments:

Miltefosine